Recent Updates
Recently added Catalysts
ARWR Positive Sentiment

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Key Takeaway: Arrowhead Pharmaceuticals announced inducement grants for 203 new employees, approved by its Compensation Committee on October 22, 2026. The grants will provide a total of 196,885 restricted stock units. This move aims to attract talent and enhance employee retention.

Market Sentiment Analysis

POSITIVE FACTORS

  • Inducement grants approved for 203 new employees.
  • Total of 196,885 restricted stock units granted.
  • Supports company growth and employee retention.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+4%
120-day peak, hindsight
Typical move
7.2%
average across 8 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Plozasiran
Phase 3 · Severe Hypertriglyceridemia

Full Press Release Details

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 22, 2026, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 203 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 196,885 restricted stock units. The grants are outside the Company’s stockholder-approv

Frequently Asked Questions

What are the inducement grants by Arrowhead Pharmaceuticals?

Arrowhead approved inducement grants for 203 new employees.

How many restricted stock units were granted?

A total of 196,885 restricted stock units were granted.

When were the inducement grants approved?

The grants were approved on October 22, 2026.

Who approved the inducement grants?

The Compensation Committee of the Board of Directors approved the grants.

Last updated: Nov 17, 2026